Successful capital increase for Biophytis with u20ac2.3 million raised
Biophytis is announcing it has successfully completed its fundraising round for a total amount of u20ac2.3M through capital increases with cancellation of the shareholders’ preferential subscription rights to the benefit of professional investors up to u20ac1.9M on the one hand, and to the benefit of individual investors via the PrimaryBid platform up to u20ac0.4M on the other hand.
Stanislas Veillet, CEO of Biophytis stated: u201cOn behalf of Biophytis team, I would like to warmly thank all of the professional investors, historical Companyu2019s investors, for their support, and retail investors through PrimaryBid who participated in this fundraising. This transaction will allow us to file regulatory applications for Marketing Authorisation in Europe and the United States for Sarconeos (BIO101) in the treatment of severe forms of COVID-19u201d.
- Success of the placement with professional investors, historical supporters of the Company, for an amount of u20ac1.9M.
- Strong participation of retail investors via the PrimaryBid platform with an offer allocated to u20ac0.4M.
- Funds raised to finance the Marketing Authorisation Applications of Sarconeos (BIO101) for the treatment of severe forms of COVID-19.
